– USA, CA – Unnatural Products, Inc., a biotech developing orally delivered macrocyclic peptides to address previously undruggable targets, announced the appointments of Abbas Kazimi and Mert Aktar to its Board of Directors.
About Abbas Kazimi
Abbas Kazimi is CBO at Nimbus Therapeutics and has been instrumental in driving key corporate initiatives that have secured over $600 million in equity financing and over $7 billion in strategic transactions, including approximately $4.5 billion returned to Nimbus’ equity holders. In his role overlooking Nimbus’ business operations, he led the expansion of Nimbus’ computational drug discovery engine and forged strategic alliances with global pharmaceutical partners. Most recently, Abbas Kazimi led the $6 billion acquisition of Nimbus’ allosteric TYK2 inhibitor program and its subsidiary. He also managed the $1.2 billion sale of Nimbus’ clinical NASH program and subsidiary to Gilead, a collaboration with Eli Lilly for Nimbus’ AMPK program, and alliances with Celgene and Genentech in immunology and immuno-oncology. PBeforeNimbus, Abbas Kazimi spent a decade advising life sciences companies globally on strategic transactions with industry partners and financial investors.
Abbas Kazimi holds an M.A. from Harvard University and a B.A. from the University of Texas at Austin.
About Mert Aktar
Mert Aktar is a seasoned life sciences executive with over 20 years of global experience bridging science and business in pharmaceuticals and biotechnology. He serves as the CEO of Receptive Bio and holds Board positions with Kyverna Therapeutics (Nasdaq: KYTX), ReAlta Life Sciences, and UCLA Technology Development Group. Before joining Receptive Bio, Mert Aktar was SVP and Global Head of Corporate Development & Strategy at Kite Pharma. In this position, he played a key role in establishing Kite’s global leadership in cell therapy, architecting strategy, and executing numerous deals, which strengthened Kite’s R&D portfolio and drove its global expansion. Previously, Mert Aktar held senior leadership positions at various biotech and large pharma organizations, across diverse modalities and therapeutic areas. Most notably, he helped shape Shire’s transformation into a global rare disease leader, facilitating numerous multi-billion-dollar transactions as Global Head of Hematology and Immunology Business Development.
Mert Aktar holds an MBA from MIT Sloan School of Management, an M.S. in Engineering Management from Tufts University, and a B.S. in Chemical Engineering from Worcester Polytechnic Institute.
About Unnatural Products, Inc.
Unnatural Products, Inc., a California biotech company, has developed a platform that addresses the complexities of medicinal chemistry in the macrocycle space through a combination of parallel experimentation and machine learning. Founded by macrocycle pioneers whose academic work uncovered how Nature’s macrocycles work, UNP is developing a portfolio of therapeutic macrocycles against high-value and traditionally difficult-to-drug targets.
For more information: https://www.unnaturalproducts.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.